Itzel Guadalupe Salazar Valencia

Prof. Itzel Guadalupe Salazar Valencia

Universidad Nacional Autónoma de México, Mexico City, Ciudad de México, Mexico

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2022 in Genes
Verified
Journal Article
Open access
PDF file
Itzel Guadalupe Salazar ValenciaItzel Guadalupe Salazar Valencia
Itzel Guadalupe Salazar Valencia
HVHugo Villamil-Ramírez
Hugo Villamil-Ramírez
FBFrancisco Barajas-Olmos
Francisco Barajas-Olmos
MGMartha Guevara-Cruz
Martha Guevara-Cruz
LMLuis Rodrigo Macias
Luis Rodrigo Macias
SCSamuel Canizales-Quinteros
Samuel Canizales-Quinteros
The loss of function melanocortin 4-receptor (MC4R) Ile269Asn mutation has been proposed as one of the most important genetic contributors to obesity in the Mexican population. However, whether patients bearing this mutation respond differently to weight loss treatments is unknown. We tested the association of this mutation with obesity in 1683 Mexican adults, and compared the response of mutation carriers and non-carriers to three different weight loss interventions: dietary restriction intervention, phentermine 30 mg/day treatment, and Roux-en-Y gastric bypass (RYGB) surgery. The Ile269Asn mutation was associated with obesity [OR = 3.8, 95% CI (1.5–9.7), p = 0.005]. Regarding interventions, in the dietary restriction group only two patients were MC4R Ile269Asn mutation carriers. After 1 month of treatment, both mutation carriers lost weight: −4.0 kg (−2.9%) in patient 1, and −1.8 kg (−1.5%) in patient 2; similar to the mean weight loss observed in six non-carrier subjects (−2.9 kg; −2.8%). Phentermine treatment produced similar weight loss in six carriers (−12.7 kg; 15.5%) and 18 non-carriers (−11.3 kg; 13.6%) after 6 months of pharmacological treatment. RYGB also caused similar weight loss in seven carriers (29.9%) and 24 non-carriers (27.8%), 6 months after surgery. Our findings suggest that while the presence of a single MC4R loss of function Ile269Asn allele significantly increases obesity risk, the presence of at least one functional MC4R allele seems sufficient to allow short-term weight loss in response to dietary restriction, phentermine and RYGB. Thus, these three different interventions may be useful for the short-term treatment of obesity in MC4R Ile269Asn mutation carriers.

1 December 2024 in Biomolecules
Verified
Journal Article
Open access
PDF file
AGAdriana Gutiérrez-Hoya
Adriana Gutiérrez-Hoya
IGIván Ortiz Garrido
Iván Ortiz Garrido
Itzel Guadalupe Salazar ValenciaItzel Guadalupe Salazar Valencia
Itzel Guadalupe Salazar Valencia
CHChristopher Bryan Romero Hernández
Christopher Bryan Romero Hernández
AVArturo Valle-Mendiola
Arturo Valle-Mendiola
ISIsabel Soto-Cruz
Isabel Soto-Cruz
Cervical cancer is a global health problem; therapies focused on eliminating tumour cells and strengthening different immunotherapies are in development. However, it has been observed that cervical tumour cells can evade cell death mechanisms and generate immune system molecules to promote their proliferation and metastasis. In this context, we analysed the role of the IL-2 and CD95 pathways, essential molecules in activating the immune system and eliminating tumour cells. However, it is important to analyse their role in cervical tumour cells because these cells could be using these pathways to proliferate. In this study, we found that SiHa and HeLa cells respond to treatment, with 10 IU/mL of IL-2 inducing their proliferation and 100 IU/mL of IL-2 decreasing their proliferation. We also observed that they express a high percentage of the CD95 receptor and its ligand (CD95L) and that treatment with CD95 agonist antibodies at low doses increases cell proliferation. Furthermore, simultaneous treatment with high doses of IL-2 plus CD95 agonist antibody positively regulates LC3B accumulation. We did not observe apoptosis under any of the treatments carried out. In conclusion, cervical tumour cells can use the IL-2 and CD95 pathways to induce their proliferation and potentially activate cytoprotective mechanisms for survival.